Drug intelligence / Profile preview

S100A4 shRNA

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral, Intravenous, Parenteral
01

Overview

S100A4 shRNA is an experimental research construct designed to silence the expression of the S100A4 gene (also known as Mts1) through RNA interference (RNAi). S100A4 is a calcium-binding protein that plays a critical role in promoting cancer metastasis, cell migration, invasion, and survival. The shRNA is typically delivered into target cells using lentiviral vectors or plasmid expression systems. In preclinical studies, S100A4 shRNA has demonstrated the ability to inhibit tumor growth and metastasis in various malignancies, including acute myeloid leukemia (AML), colorectal cancer, and non-small cell lung cancer. In AML, silencing S100A4 has been shown to induce apoptosis by upregulating NCOA7 and activating V-ATPase-mediated cytoplasmic acidification. It is primarily used as a laboratory tool by academic researchers and does not currently have a commercial developer or regulatory approval.

Other names
Mts1 shRNAMts-1 shRNAMts 1 shRNAS100 calcium-binding protein A4 short hairpin RNAS-100 calcium-binding protein A4 short hairpin RNAS 100 calcium-binding protein A4 short hairpin RNA
02

Targets

S100 calcium-binding protein A4 (S100A4) mRNA

Beyond the preview

Go deeper on S100A4 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on S100A4 shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call